ESH 2019 | Why should we target RUNX1 in AML treatment?


The AML Global Portal were delighted to speak to Guy Sauvageau, Maisonneuve-Rosemont Hospital, Montreal, CA, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Guy Sauvageau: Why should we target RUNX1 in AML treatment?

Guy Sauvageau explains targeting RUNX1 in AML treatment. He explains different subsets of genetic mutations confer different treatment response and discusses his work in identifying small molecule compounds that aims to reinstate sensitivity to treatment in a specific subset of AML.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative